Study Design and Outcomes of the Phase II REFINE Trial

A review of the study design and key efficacy and safety outcomes of the REFINE trial studying ruxolitinib plus navitoclax treatment in myelofibrosis.

EP: 1.An Overview of Myelofibrosis

EP: 2.The Role of Biomarker Testing in Patients with Myelofibrosis

EP: 3.Current Treatment Options in Myelofibrosis

Now Viewing

EP: 4.Study Design and Outcomes of the Phase II REFINE Trial

EP: 5.Potential Implications of the REFINE Trial on the Myelofibrosis Treatment Paradigm

EP: 6.Investigational Agents and Unmet Needs in Myelofibrosis Treatment

Related Videos